

UNIT TERMINAL OBJECTIVE

- 5-4 At the completion of this unit, the paramedic student will be able to integrate pathophysiological principles and assessment findings to formulate a field impression and implement a treatment plan for the patient with an endocrine problem.

COGNITIVE OBJECTIVE

At the completion of this unit, the paramedic student will be able to:

- 5-4.1 Describe the incidence, morbidity and mortality of endocrinologic emergencies. (C-1)
- 5-4.2 Identify the risk factors most predisposing to endocrinologic disease. (C-1)
- 5-4.3 Discuss the anatomy and physiology of organs and structures related to endocrinologic diseases. (C-1)
- 5-4.4 Review the pathophysiology of endocrinologic emergencies. (C-1)
- 5-4.5 Discuss the general assessment findings associated with endocrinologic emergencies. (C-1)
- 5-4.6 Identify the need for rapid intervention of the patient with endocrinologic emergencies. (C-1)
- 5-4.7 Discuss the management of endocrinologic emergencies. (C-1)
- 5-4.8 Describe osmotic diuresis and its relationship to diabetes. (C-1)
- 5-4.9 Describe the pathophysiology of adult onset diabetes mellitus. (C-1)
- 5-4.10 Describe the pathophysiology of juvenile onset diabetes mellitus. (C-1)
- 5-4.11 Describe the effects of decreased levels of insulin on the body. (C-1)
- 5-4.12 Correlate abnormal findings in assessment with clinical significance in the patient with a diabetic emergency. (C-3)
- 5-4.13 Discuss the management of diabetic emergencies. (C-1)
- 5-4.14 Integrate the pathophysiological principles and the assessment findings to formulate a field impression and implement a treatment plan for the patient with a diabetic emergency. (C-3)
- 5-4.15 Differentiate between the pathophysiology of normal glucose metabolism and diabetic glucose metabolism. (C-3)
- 5-4.16 Describe the mechanism of ketone body formation and its relationship to ketoacidosis. (C-1)
- 5-4.17 Discuss the physiology of the excretion of potassium and ketone bodies by the kidneys. (C-1)
- 5-4.18 Describe the relationship of insulin to serum glucose levels. (C-1)
- 5-4.19 Describe the effects of decreased levels of insulin on the body. (C-1)
- 5-4.20 Describe the effects of increased serum glucose levels on the body. (C-1)
- 5-4.21 Discuss the pathophysiology of hypoglycemia. (C-1)
- 5-4.22 Discuss the utilization of glycogen by the human body as it relates to the pathophysiology of hypoglycemia. (C-3)
- 5-4.23 Describe the actions of epinephrine as it relates to the pathophysiology of hypoglycemia. (C-3)
- 5-4.24 Recognize the signs and symptoms of the patient with hypoglycemia. (C-1)
- 5-4.25 Describe the compensatory mechanisms utilized by the body to promote homeostasis relative to hypoglycemia. (C-1)
- 5-4.26 Describe the management of a responsive hypoglycemic patient. (C-1)
- 5-4.27 Correlate abnormal findings in assessment with clinical significance in the patient with hypoglycemia. (C-1)
- 5-4.28 Discuss the management of the hypoglycemic patient. (C-1)
- 5-4.29 Integrate the pathophysiological principles and the assessment findings to formulate a field impression and implement a treatment plan for the patient with hypoglycemia. (C-3)
- 5-4.30 Discuss the pathophysiology of hyperglycemia. (C-1)
- 5-4.31 Recognize the signs and symptoms of the patient with hyperglycemia. (C-1)
- 5-4.32 Describe the management of hyperglycemia. (C-1)
- 5-4.33 Correlate abnormal findings in assessment with clinical significance in the patient with hyperglycemia. (C-3)
- 5-4.34 Discuss the management of the patient with hyperglycemia. (C-1)
- 5-4.35 Integrate the pathophysiological principles and the assessment findings to formulate a field impression

- and implement a treatment plan for the patient with hyperglycemia. (C-3)
- 5-4.36 Discuss the pathophysiology of nonketotic hyperosmolar coma. (C-1)
- 5-4.37 Recognize the signs and symptoms of the patient with nonketotic hyperosmolar coma. (C-1)
- 5-4.38 Describe the management of nonketotic hyperosmolar coma. (C-1)
- 5-4.39 Correlate abnormal findings in assessment with clinical significance in the patient with nonketotic hyperosmolar coma. (C-3)
- 5-4.40 Integrate the pathophysiological principles and the assessment findings to formulate a field impression and implement a treatment plan for the patient with nonketotic hyperosmolar coma. (C-3)
- 5-4.41 Discuss the management of the patient with hyperglycemia. (C-1)
- 5-4.42 Integrate the pathophysiological principles and the assessment findings to formulate a field impression and implement a treatment plan for the patient with hyperglycemia. (C-3)
- 5-4.43 Discuss the pathophysiology of diabetic ketoacidosis. (C-1)
- 5-4.44 Recognize the signs and symptoms of the patient with diabetic ketoacidosis. (C-1)
- 5-4.45 Describe the management of diabetic ketoacidosis. (C-1)
- 5-4.46 Correlate abnormal findings in assessment with clinical significance in the patient with diabetic ketoacidosis. (C-3)
- 5-4.47 Discuss the management of the patient with diabetic ketoacidosis. (C-1)
- 5-4.48 Integrate the pathophysiological principles and the assessment findings to formulate a field impression and implement a treatment plan for the patient with diabetic ketoacidosis. (C-3)
- 5-4.49 Discuss the pathophysiology of thyrotoxicosis. (C-1)
- 5-4.50 Recognize signs and symptoms of the patient with thyrotoxicosis. (C-1)
- 5-4.51 Describe the management of thyrotoxicosis. (C-1)
- 5-4.52 Correlate abnormal findings in assessment with clinical significance in the patient with thyrotoxicosis. (C-3)
- 5-4.53 Discuss the management of the patient with thyrotoxicosis. (C-1)
- 5-4.54 Integrate the pathophysiological principles and the assessment findings to formulate a field impression and implement a treatment plan for the patient with thyrotoxicosis. (C-3)
- 5-4.55 Discuss the pathophysiology of myxedema. (C-1)
- 5-4.56 Recognize signs and symptoms of the patient with myxedema. (C-1)
- 5-4.57 Describe the management of myxedema. (C-1)
- 5-4.58 Correlate abnormal findings in assessment with clinical significance in the patient with myxedema. (C-3)
- 5-4.59 Discuss the management of the patient with myxedema. (C-1)
- 5-4.60 Integrate the pathophysiological principles and the assessment findings to formulate a field impression and implement a treatment plan for the patient with myxedema. (C-3)
- 5-4.61 Discuss the pathophysiology of Cushing's syndrome. (C-1)
- 5-4.62 Recognize signs and symptoms of the patient with Cushing's syndrome. (C-1)
- 5-4.63 Describe the management of Cushing's syndrome. (C-1)
- 5-4.64 Correlate abnormal findings in assessment with clinical significance in the patient with Cushing's syndrome. (C-3)
- 5-4.65 Discuss the management of the patient with Cushing's syndrome. (C-1)
- 5-4.66 Integrate the pathophysiological principles and the assessment findings to formulate a field impression and implement a treatment plan for the patient with Cushing's syndrome. (C-3)
- 5-4.67 Discuss the pathophysiology of adrenal Insufficiency. (C-1)
- 5-4.68 Recognize signs and symptoms of the patient with adrenal insufficiency. (C-1)
- 5-4.69 Describe the management of adrenal insufficiency. (C-1)
- 5-4.70 Correlate abnormal findings in assessment with clinical significance in the patient with adrenal insufficiency. (C-3)
- 5-4.71 Discuss the management of the patient with adrenal insufficiency. (C-1)
- 5-4.72 Integrate the pathophysiological principles and the assessment findings to formulate a field impression and implement a treatment plan for the patient with adrenal insufficiency. (C-3)
- 5-4.73 Integrate the pathophysiological principles to the assessment of a patient with a endocrinological

- emergency. (C-3)
- 5-4.74 Differentiate between endocrine emergencies based on assessment and history. (C-3)
- 5-4.75 Correlate abnormal findings in the assessment with clinical significance in the patient with endocrinologic emergencies. (C-3)
- 5-4.76 Develop a patient management plan based on field impression in the patient with an endocrinologic emergency. (C-3)

AFFECTIVE OBJECTIVES

None identified for this unit.

PSYCHOMOTOR OBJECTIVES

None identified for this unit.

DECLARATIVE

- I. Introduction
 - A. Epidemiology
 - 1. Incidence
 - 2. Mortality/ morbidity
 - 3. Risk factors
 - 4. Prevention strategies
 - B. Anatomy and physiology
- II. General pathophysiology, assessment and management
 - A. Pathophysiology
 - 1. Endocrine system
 - a. Integrated chemical and coordination system enabling
 - (1) Reproduction
 - (2) Growth and development
 - (3) Regulation of energy
 - b. Works with the nervous system to help
 - (1) Maintain an internal homeostasis of the body
 - (2) Coordinate responses to environmental changes and stress
 - c. Composed of glands or glandular tissue that synthesize, store and secrete chemical messengers (hormones) that affect specific target organs and body tissues
 - d. Specificity of this system is determined by the affinity of receptors on target organs and body tissues to a particular hormone
 - 2. Endocrine glands
 - a. Ductless glands
 - (1) Highly vascular
 - (2) Synthesize and secrete hormones
 - (3) Specific glands
 - (a) Hypothalamus
 - (b) Pituitary
 - (c) Thyroid
 - (d) Parathyroid
 - (e) Adrenal
 - (f) Kidneys
 - (g) Pancreatic islets
 - (h) Ovaries
 - (i) Testes
 - (j) Hormones
 - (4) Common characteristics
 - (a) Circulation through the blood
 - (b) Secretion of minute but effective amounts at predictable but variable intervals bind to specific cellular receptors to change intercellular metabolism
 - (5) Structure
 - B. Assessment findings
 - 1. Scene size-up
 - a. Scene safety
 - b. Personal protective equipment (PPE)

- (1) General impression
 - (2) Trauma
 - (a) Responsive
 - (b) Unresponsive
 - (3) Medical
 - (a) Responsive
 - (b) Unresponsive
 - c. Nature of illness
 - 2. Initial assessment
 - a. Airway
 - b. Breathing
 - c. Circulation
 - d. Disability
 - e. Chief complaint
 - 3. Focused history
 - a. Onset
 - b. Provoking factors
 - c. Time
 - d. Nausea/ vomiting
 - e. Weight loss
 - f. Last meal
 - g. Non-specific
 - h. Changes in
 - (1) Energy level
 - (2) Alertness
 - (3) Sleep patterns
 - (4) Mood
 - (5) Affect
 - (6) Weight
 - (7) Skin
 - (8) Hair
 - (9) Personal appearance
 - (10) Sexual function
 - i. Specific history of
 - (1) Hypopituitarism
 - (2) Hypothyroidism
 - (3) Polydipsia
 - (4) Polyuria
 - (5) Polyphagia
 - (6) Diabetes
 - (7) Exophthalmus in hyperthyroidism
 - 4. Focused physical examination
 - a. Appearance
 - b. Level of consciousness
 - c. Apparent state of health
 - d. Skin color
 - e. Vital signs
- C. Management/ treatment plan
- 1. Airway and ventilatory support
 - a. Maintain an open airway

- b. High flow oxygen
- 2. Circulatory support
 - a. Monitor blood pressure
- 3. Pharmacological interventions
 - a. Consider initiating intravenous line
 - b. Avoid interventions which mask signs and symptoms
- 4. Non-pharmacological interventions
 - a. Monitor LOC
 - b. Monitor vital signs
- 5. Transport consideration
 - a. Appropriate mode
 - b. Appropriate facility
- 6. Psychological support
 - a. All actions reflect a calm, caring, competent attitude
 - b. Keep patient and significant others informed of your actions

III. Specific illnesses

A. Diabetes mellitus

- 1. Epidemiology
 - a. Incidence
 - b. Morbidity/ mortality
 - c. Long term complications
 - d. Risk factors
 - e. Prevention strategies
- 2. Anatomy and physiology review
- 3. Pathophysiology
 - a. Types
 - (1) Type I-insulin dependent
 - (2) Type II-non insulin dependent
 - b. A chronic system syndrome characterized by hyperglycemia caused by a decrease in the secretion or activity of insulin
 - c. Normal insulin metabolism
 - (1) Produced by beta cells in the islets of Langerhans
 - (2) Continuously released into the bloodstream
 - (a) Insulin is released from the beta cells as proinsulin
 - (b) Routed through the liver where 50-70 percent is extracted from the blood
 - (c) The level of plasma insulin rises after a meal
 - i) Stimulates storage of glucose as glycogen, liver and muscle tissue
 - ii) Enhances fat deposition in adipose tissue
 - iii) Inhibits protein degradation
 - iv) Accelerates protein synthesis
 - (d) The fall of plasma insulin levels during normal overnight fasting facilitates the release of
 - i) Stored glucose from the liver
 - ii) Protein from muscle tissue
 - iii) Fat from adipose tissue
 - (e) Average daily secretion is 0.6 units per kilogram of body weight
 - (3) Activity of released insulin

- (a) Lowers blood glucose levels
 - (b) Facilitates a stable, normal glucose range of approximately 70 to 120 mg/ dl
 - d. Ketone formation
 - (1) When insulin supply is insufficient, glucose cannot be used for cellular energy
 - (2) Response to cellular starvation
 - (3) Body releases and breaks down stored fats and protein to provide energy
 - (4) Free fatty acids from stored triglycerides are released and metabolized in the liver in such large quantities that ketones are formed
 - (5) Excess ketones upset the pH balance and acidosis develops
 - (6) Gluconeogenesis from protein is the last source used by the body as a compensatory response to provide cellular energy
 - (a) Results in an increase in glucose and nitrogen
 - (b) Due to prevailing insulin insufficiency, the glucose can not be used resulting in
 - i) Increased osmotic diuresis
 - ii) Dehydration and loss of electrolytes, particularly potassium
 - 4. Assessment findings
 - a. History
 - (1) Has insulin dosage changed recently?
 - (2) Has the patient had a recent infection?
 - (3) Has the patient suffered any psychologic stress?
 - b. Signs and symptoms
 - (1) Altered mental status
 - (2) Abnormal respiratory pattern (Kussmaul's breathing)
 - (3) Tachycardia
 - (4) Hypotension
 - (5) Breath has a distinct fruity odor
 - (6) Polydipsia
 - (7) Polyphagia
 - (8) Warm dry skin
 - (9) Weight loss
 - (10) Weakness
 - (11) Dehydration
 - 5. Management
 - a. Airway and ventilation
 - b. Circulation
 - c. Pharmacological interventions
 - d. Non-pharmacological interventions
 - e. Transport consideration
 - (1) Appropriate mode
 - (2) Appropriate facility
 - f. Psychological support/ communication strategies
- B. Hypoglycemia
- 1. Epidemiology
 - a. Incidence
 - b. Morbidity/ mortality
 - c. Risk factors

- d. Prevention strategies
 - 2. Pathophysiology
 - a. Blood glucose levels fall below that required for normal body functioning
 - b. Combined effects of a decreased energy supply to the central nervous system and a hyperadrenergic state results from a compensatory increase in catecholamine secretion
 - (1) Tremors
 - (2) Diaphoresis
 - (3) Palpitations
 - (4) Tachycardia
 - (5) Pale, cool skin
 - (6) Low levels of blood glucose reaching the brain results in an altered mental status
 - (7) Irritability
 - (8) Confusion
 - (9) Stupor
 - (10) Coma
 - 3. Assessment
 - a. Known history of
 - (1) Diabetes
 - (2) Prolonged fasting
 - (3) Alcoholism
 - b. Signs and symptoms
 - (1) Weakness
 - (2) Irritability
 - (3) Hunger
 - (4) Confusion
 - (5) Anxiety
 - (6) Bizarre behavior
 - (7) Tachycardia
 - (8) Normal respiratory pattern
 - (9) Cool, pale skin
 - (10) Diaphoresis
 - 4. Management
 - a. Airway and ventilation
 - b. Circulation
 - c. Pharmacological interventions
 - d. Non-pharmacological interventions
 - e. Transport consideration
 - (1) Appropriate mode
 - (2) Appropriate facility
 - (3) Psychological support/ communication strategies
- C. Hyperglycemia (hyperglycemic hyperosmolar nonketosis)
 - 1. Epidemiology
 - a. Incidence
 - b. Mortality/ morbidity
 - c. Risk factors
 - d. Prevention strategies
 - 2. Pathophysiology
 - a. Occurs in patients with diabetes who are able to produce enough insulin to

- prevent DKA but not enough to prevent severe hyperglycemia, osmotic diuresis and extracellular fluid depletion
 - b. Increasing blood glucose levels causes a fluid shift from intracellular to extracellular spaces
 - 3. Assessment
 - a. Known history of
 - (1) Diabetes
 - (2) Inadequate fluid intake
 - b. Signs and symptoms
 - (1) Neurologic abnormalities
 - (a) Somnolence
 - (b) Coma
 - (c) Seizures
 - (d) Hemiparesis
 - (e) Aphasia
 - (f) Increasing mental depression
 - (g) Dehydration
 - (h) Polydipsia
 - (i) Polyuria
 - (j) Polyphagia
 - 4. Management
 - a. Airway and ventilatory support
 - b. Circulation
 - c. Pharmacological interventions
 - d. Non-pharmacological interventions
 - e. Transport consideration
 - (1) Appropriate mode
 - (2) Appropriate facility
 - f. Psychological support/ communication strategies
- D. Diabetic ketoacidosis
- 1. Epidemiology
 - a. Incidence
 - b. Mortality/ morbidity
 - c. Risk factors
 - d. Prevention strategies
 - e. Anatomy and physiology review
 - 2. Pathophysiology
 - a. Hyperglycemia
 - b. Ketonemia
 - c. Relative insulin insufficiency
 - d. Counterregulatory hormone excess
 - 3. Assessment findings
 - a. History
 - (1) General health
 - (2) Previous medical conditions
 - (3) Medications
 - (4) Previous experience with complaint
 - (5) Time of onset
 - b. Physical
 - (1) Dehydration

- (2) Hypotension
 - (3) Reflex tachycardia
 - (4) Acetone (fruity) odor on breath
 - (5) Nausea
 - (6) Vomiting
 - (7) Abdominal pain
 - (8) Hyperventilation
 - (9) Kussmaul's respiration
- 4. Management
 - a. Airway and ventilatory support
 - (1) Oxygen
 - (2) Positioning
 - (3) Suction
 - (4) Assisted ventilation
 - (5) Suction
 - (6) Advanced airway devices
 - b. Circulatory support
 - (1) Venous access
 - (2) Blood analysis
 - c. Non-pharmacological interventions
 - (1) General comfort measures
 - d. Pharmacological interventions
 - (1) Rehydration
 - (2) Bicarbonate
 - (3) Potassium
 - (4) Insulin
 - e. Psychological support
 - f. Transport considerations
 - (1) Appropriate mode
 - (2) Appropriate facility
- E. Thyrotoxicosis (thyroid storm)
 - 1. Epidemiology
 - a. Incidence
 - b. Mortality/ morbidity
 - c. Risk factors
 - d. Prevention strategies
 - 2. Pathophysiology
 - a. Acute manifestation of all hyperthyroid symptoms
 - b. Excessive circulating level of thyroxine and triiodothyronine
 - (1) Regulate metabolism
 - (2) Regulate growth and development
 - 3. Assessment
 - a. History
 - b. Signs and symptoms
 - (1) Severe tachycardia
 - (2) Heart failure
 - (3) Cardiac dysrhythmias
 - (4) Shock
 - (5) Hyperthermia
 - (6) Restlessness

- (7) Agitation
 - (8) Abdominal pain
 - (9) Delirium
 - (10) Coma
 - 4. Management
 - a. Airway and ventilation
 - b. Circulation
 - c. Pharmacological interventions
 - (1) Anti-thyroid drugs - in hospital management
 - (2) Beta adrenergic receptor blockers
 - d. Non-pharmacological interventions
 - e. Transport consideration
 - (1) Appropriate mode
 - (2) Appropriate facility
 - f. Psychological support/ communication strategies
 - F. Myxedema (adult hypothyroidism)
 - 1. Epidemiology
 - a. Incidence
 - b. Mortality/ morbidity
 - c. Risk factors
 - d. Prevention strategies
 - 2. Pathophysiology
 - a. A disease caused by hyposecretion of the thyroid gland during the adult years
 - 3. Assessment
 - a. History
 - b. Signs and symptoms
 - (1) Edematous face
 - (2) Periorbital edema
 - (3) Mask-like effect
 - (4) Impaired memory
 - (5) Slowed speech
 - (6) Decreased initiative
 - (7) Somnolence
 - (8) Cold intolerance
 - (9) Dry, coarse skin
 - (10) Muscle weakness and swelling
 - (11) Constipation
 - (12) Weight gain
 - (13) Hair loss
 - (14) Hoarseness
 - 4. Management
 - a. Airway and ventilation
 - b. Circulation
 - c. Pharmacological interventions
 - d. Non-pharmacological interventions
 - e. Transport consideration
 - (1) Appropriate mode
 - (2) Appropriate facility
 - f. Psychological support/ communication strategies
- IV. Corticosteroid excess - Cushing's syndrome

- A. Epidemiology
 - 1. Incidence
 - 2. Mortality/ morbidity
 - 3. Risk factors
 - 4. Prevention strategies
- B. Pathophysiology
 - 1. A spectrum of clinical abnormalities caused by an excess of corticosteroids, especially glucocorticoids
 - 2. Causes
 - a. Corticotropin secreting pituitary tumor
 - b. Cortical secreting neoplasm within the adrenal cortex
 - c. Excess secretion of corticotropin by a malignant growth outside the adrenal
 - d. Prolongs administration of high dose corticosteroids
- C. Assessment
 - 1. History
 - 2. Signs and symptoms
 - a. Thinning hair
 - b. Acnes
 - c. Hump on back of neck (buffalo hump)
 - d. Supraclavicular fat pad
 - e. Thin extremities
 - f. Ecchymosis
 - g. Slow healing
 - h. Pendulous abdomen
 - i. Weight gain
 - j. Increased body and facial hair
- D. Management
 - 1. Airway and ventilation
 - 2. Circulation
 - 3. Pharmacological interventions
 - 4. Non-pharmacological interventions
 - 5. Transport consideration
 - a. Appropriate mode
 - b. Appropriate facility
 - 6. Psychological support/ communication strategies
- V. Adrenal insufficiency - Addison's disease
 - A. Epidemiology
 - 1. Incidence
 - 2. Mortality/ morbidity
 - 3. Risk factors
 - 4. Prevention strategies
 - B. Pathophysiology
 - 1. Adrenal insufficiency
 - a. Adrenal steroids are reduced
 - (1) Glucocorticoids
 - (2) Mineralocorticoids
 - (3) Androgens
 - 2. Most common cause is idiopathic atrophy of adrenal tissue
 - 3. Less common caused include hemorrhage, infarctions, fungal infections and acquired

- immune deficiency disease
 - C. Assessment
 - 1. History
 - 2. Signs and symptoms
 - a. Progressive weakness
 - b. Progressive weight loss
 - c. Progressive anorexia
 - d. Skin hyperpigmentation
 - (1) Areas exposed to the sun
 - (2) Areas exposed to pressure points
 - (3) Joints and creases
 - e. Hypotension
 - f. Hyponatremia
 - g. Hyperkalemia
 - h. Nausea
 - i. Vomiting
 - j. Diarrhea
 - D. Management
 - 1. Airway and ventilation
 - 2. Circulation
 - 3. Pharmacological interventions
 - 4. Non-pharmacological interventions
 - 5. Transport consideration
 - a. Appropriate mode
 - b. Appropriate facility
 - 6. Psychological support/ communication strategies
- VI. Integration